TPEX
24.5.2021 11:02:13 CEST | Business Wire | Press release
The Taipei Exchange, TPEx, launched a dedicated segment for sustainable bonds, celebrating on May 18 with the debut of three social bond listings. The segment marks a milestone for Taiwan’s socially responsible investment and is in accordance with a plan announced by the Taiwanese government’s Financial Supervisory Commission (FSC). The commission’s plan, named the Green Finance Action Plan 2.0, was announced in August 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210524005043/en/
TPEx Chairman Philip Chen said in a statement announcing the new segment, “After accomplishing the mechanism regarding social bonds, the last piece of the puzzle, TPEx has integrated the regulations of Green Bonds, Sustainability Bonds, and Social Bonds and launched this segment exclusively for ESG concept bonds.” Chen went on to highlight TPEx’s market acclaim for launching Green Bond and Sustainability Bond operational directions in 2017 and 2020 respectively, which were in line with the ICMA’s GBP and SBG. The total outstanding amount of listed sustainable bonds has steadily grown, exceeding NT$207bn (US$7bn), according to Chen.
The first batch of three social bonds listed on TPEx is primarily funding socioeconomic advancement projects related to the global COVID-19 pandemic, projects such as increasing access to loans, providing job opportunities and raising the availability of affordable housing.
FSC Chairman Dr. Tien-Mu Huang said, “FSC fully supports financial innovation and product diversity. The Sustainable Bond Segment at TPEx provides the market with a clearer, more complete and consistent regulatory mechanism, facilitating easier compliance for issuers. This subsequently serves to direct funds to eco-friendly and socially beneficial projects, helping achieve the goals of Green Finance Action Plan 2.0 tremendously.” Mrs. Tania Berchem from the Luxemburg Trade and Investment Office in Taipei, Mr. Nicholas Pfaff from ICMA, and Mr. Sean Kidney from CBI all sent their congratulatory messages to TPEx for the dedicated segment.
Meanwhile, TPEx has modernized its sustainable bonds website (https://www.tpex.org.tw/web/bond/sustainability/index.php?l=en-us ), improving all relevant information for clarity and accessibility. The updated website is bilingual, and key features have been added which include issuance status and bond framework information, assessment opinions from external reviewers, market reports, and access to current sustainability studies and research reports. Speaking of the new website, Chen added, “In facilitating responsible investing, we hope to offer a full array of information to enhance transparency while simultaneously raising investors’ social awareness.”
About the Taipei Exchange
Established in 1994, the Taipei Exchange is a member of the World Federation of Exchanges. The exchange has grown with a vision of sustainability to meet the diverse needs of issuers and investors, and has long been dedicated to fostering emerging, high-tech and creative industries by providing a viable channel for raising capital. The exchange has also established a fast-growing bond market. For more information, visit: https://www.tpex.org.tw/web/index.php?l=en-us
View source version on businesswire.com: https://www.businesswire.com/news/home/20210524005043/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom